The Food and Drug Administration (FDA) is requiring labeling for fluoroquinolone antibiotics to include a black box warning that patients taking these drugs are at increased risk of tendinitis and tendon rupture.
Despite an existing warning that fluoroquinolones may increase the risk of tendon rupture, a recent FDA analysis revealed that the agency continues to receive many reports of tendon-related adverse events among patients taking these drugs. In addition to the black box warning, the manufacturers of fluoroquinolones are being required to provide medication guides outlining the risk.
Kuehn BM. Fluoroquinolone Warning. JAMA. 2008;300(8):891. doi:10.1001/jama.300.8.891-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: